產(chǎn)品詳情

  • 產(chǎn)品名稱：MK-2206

  • 產(chǎn)品型號：
  • 產(chǎn)品廠商：Biovision
  • 產(chǎn)品文檔：
你添加了1件商品 查看購物車
簡單介紹：
MK-2206
詳情介紹：
Characteristics A highly selective non-ATP competitive allosteric Akt inhibitor with IC50,'s of 8 nM, 2 nM and 65 nM for Akt1, Akt2 and Akt3, respectively. MK-2206 potently inhibits phosphorylation of Thr308 and Ser473 in 3T3-L1 adipocytes with IC50 values of 0.11 and 0.18 μM, respectively as well as downstream effects of insulin on GLUT4 translocation (IC50 = 0.47 μM) and glucose transport (IC50 = 0.14 μM). In addition, treatment with MK-2206 causes a robust, concentration-dependent activation of autophagy in human glioma cell lines LN229 and T98G.
Purity ≥ 98?% by HPLC
Chemical Name 8-(4-(1-Aminocyclobutyl)phenyl-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride
Formula C??H??N?O .2HCl
Permeability Cell-permeable
Molecular Weight 480.39 g/mol
CAS-No 1032350-13-2
Research Area Kinases/Phosphatases
Restrictions For Research Use only
Format Solid
Handling Advice Protect from air and moisture
Storage -20 °C
Expiry Date 36 months
Supplier Images
image for MK-2206 (ABIN629259) MK-2206
Product cited in: Cheng, Whitsett, Tran, Winkles: "The TWEAK Receptor Fn14 is a Src-inducible Protein and a Positive Regulator of Src-driven Cell Invasion." in: Molecular cancer research : MCR, 2014 (PubMed).